nach oben

PharmacoEconomics

Erschienen in:

01.12.2004 | Review Article

Economic costs to business of the HIV/AIDS epidemic

verfasst von: Dr Gordon G. Liu, Dr Jeff J. Guo, Scott R. Smith

Erschienen in: PharmacoEconomics | Ausgabe 18/2004

Einloggen, um Zugang zu erhalten

Abstract

HIV infection is a devastating disease for individuals and society. The economic burden of employees with HIV infection is a matter of increasing concern for employers. The purpose of this paper was to conduct a comprehensive review of published studies which measured/estimated economic costs incurred by HIV-infected employees, and evaluate the potential economic impact of the HIV/AIDS epidemic on business in different countries. This review finds a conceptual consensus in the literature that suggests that the HIV/AIDS epidemic has a potentially sizable economic cost to business, primarily due to increased costs for employment-based insurance premiums, welfare benefits, lost productivity, new hiring and training, and a downsized economy and labour market.

Based on published data in the US, accounting for the first three major cost items, in 2002 an HIV-infected worker would cost an employer in the US an estimated $US37 320 for asymptomatic individuals and $US50 374 for symptomatic individuals per person-year. However, this review found little consistent empirical data in the literature regarding the scale of disease costs specific to businesses in different settings. In addition, the current literature offers little guidance in terms of well designed, validated, and easily replicated analytical frameworks for conducting a comprehensive cost analysis from a business perspective.

Future research is needed to improve both the theoretical modelling and empirical work in assessing the full economic impact of the HIV/ADIS epidemic on patients, businesses and society at large.

Trade names are used for identification purposes only and do not imply endorsement.

United Nations Program for AIDS (UNAIDS). Fighting AIDS: a new global resolve. In: report on the global HIV/AIDS epidemic 2002; 8–20 [online]. Available from URL: http://www.unaids.org [Accessed 2003 Aug 1]

Bloom DE, Rosenfield A. A moment in time: AIDS and business. AIDS Patient Care STDS 2000; 14 (9): 509–17PubMedCrossRef

United Nations Program for AIDS (UNAIDS). Report on the Global HIV/AIDS Epidemic 2000

Harmonie Toros, U.N. warns of HIV/AIDS spread. Associated Press News, USA Today, July 2, 2002 [online]. Available from URL: http://www.usatoday.com [Accessed 2003 Aug 1]

Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135 (1): 17–26PubMed

Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352 (9142): 1725–30

Patella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 228 (13): 853–60

Vittinghoff E, Scheer S, O’Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179 (3): 717–20PubMedCrossRef

Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222–35PubMedCrossRef

10.

US Department of Health and Human Services, US Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Bethesda (MD): Dept of Health and Human Services and the Henry Institutes of Health, 2001 Aug 13

11.

Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53: 2004; 558–61PubMedCrossRef

12.

Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J AIDS 1998; 1: 466–85

13.

Hettinger FJ. Forecasting the medical care costs of the HIV epidemic: 1991–1994. Inquiry 1991; 28: 356–65

14.

Scitovsky AA, Rice D. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985,1986, and 1991. Public Health Rep 1987; 102 (1): 5–17PubMed

15.

Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: F7–11PubMedCrossRef

16.

Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquit Immune Defic Syndr 1990; 3: 904–12

17.

Seage III GR, Landers S, Lamb GA, et al. Effects of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health 1990; 80: 835–9PubMedCrossRef

18.

Andrulis DP, Weslowski VB, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992; 267: 2482–6PubMedCrossRef

19.

Bozzette SA, Bery SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897–904PubMedCrossRef

20.

Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817–23PubMedCrossRef

21.

Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000; 22 (11): 1333–45PubMedCrossRef

22.

World Health Organization (WHO) and International Labor Organization (ILO). Consultation sur le sida et le lieu de travail: declaration de Geneve, Geneve, 1988 Jun 27–29

23.

Farnham PG. Defining and measuring the costs of the HIV epidemic to businesses. Public Health Rep 1994; 109 (3): 311–8PubMed

24.

Farnham G, Gorsky R. Costs to business for an HIV-infected worker. Inquiry 1994; 31: 76–88PubMed

25.

Bloom DE, Glied S. Benefits and costs of HIV testing. Science 1991 Jun 28; 252: 1798–804

26.

Whiteside A, Sumer C. AIDS: the challenge for South Africa. Cape Town: Human & Rousseau and Tafelberg, 2000; 112

27.

Liu GG, Yin DD, Lyu R, et al. Economic costs of HIV infection: an employer’s perspective. Fur J Health Econ 2002; 3: 226–34CrossRef

28.

Gershy-Damet GM, Koffit K, Soro B, et al. Seroepidemiological survery of HIV-1 and HIV-2 infections in the five regions of Ivory Coast. AIDS 1991; 5 (4): 462–3PubMedCrossRef

29.

De Cock KM. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. WHO AIDS Tech Bull 1989; 2: 157–8PubMed

30.

Breuer NL. Learning from the global village: corporate responsibility around the world: clinical care options for HIV. Medscape HIV/AIDS. 1998; 4: 4 [online]. Available from URL: http://www.medscape.com/ [Accessed 2002 May]

31.

Sebesta D, LaPlante M. HIV/AIDS, disability and employment. Disability statistics report (6). Washington, DC: National Institute on Disability and Rehabilitation Research, Department of Education, 1996

32.

Pramualratana A. Thailand Business Coalition on AIDS: businesses must face AIDS in the workplace. HIV/AIDS action in developing countries. European Union AIDS Program in developing countries. 1999 Feb 3

33.

Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (3): 223–31PubMedCrossRef

34.

Hettinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 2000; 24 (2): 182–8

35.

Cuddington IT. Further results on the macroeconomic effects of AIDS: the dualistic, labor-surplus economy. World Bank Econ Rev 1993; 7 (3): 403–17PubMedCrossRef

36.

Theodore K. HIV/AIDS in the Caribbean: economic issues: impact and investment response [online]. Available from URL: http://www.ilocarib.org.tt/infsourcesihiv aids/theodore [Accessed 2002 Oct]

37.

Hancock J, Nalo D, Aoko M, et al. The macroeconomic impact of HIV/AIDS. In: Forsythe S, Rau B, editors. AIDS in Kenya: socioeconomic impact and policy implications. Arlington (VA): Family Health International, 1996

38.

Bollinger L, Stover J, Kerkhoven R, et al. The economic impact of AIDS in Zimbabwe. Washington, (DC): Futures Group International, 1999

39.

Bollinger L, Stover J, Riwa P. The economic impact of AIDS in Tanzania. Washington (DC): The Futures Group International, 1999 Sept

40.

Machlin S, Cohen J, Zuvekas S, et al. Per Capita health care expenses 1996. Rockville (MD): Agency for Health Care Research and Quality; 2000. Highlights No. 12. AHRQ Pub. No. 00-0026

41.

Bureau of Labor Statistics (BLS). The CPI for medical care prices as fixed market basket of medical commodities and services. Compensation and Working Conditions, 1997; 3–11

42.

Kane JJ, Blostin AP, Pfuntner IN. Changing survey strategies in the evolution of health care plans. Compensation and working conditions. Washington (DC): US Department of Labor, 1996; 3–10

43.

Hyland S. Health benefits show cost containment strategies. Monthly Labor Review, US Department of Labor. Washington (DC): 1992 Feb; 42–3

44.

Burke TP. Alternatives to hospital care under employee benefit plans. Monthly Labor Review. US Department of Labor. Washington (DC): 1991; 1997, 1998, 1999, 2000, 2001, 2002. US Department of Labor [online]. Available from URL: http://www.bls.gov. [Accessed 2003 June]

45.

Schwenk AE. Trends in health insurance costs: compensation and working condition [online]. The Bureau of Labor Statistics, Spring 1999, 4 (1). Available from URL: http://www.bls.gov/opub/cwc/1999/spring/ [Accessed 2002 May]

46.

Bollinger L, Stover J, Nalo D. The economic impact of AIDS in Kenya. Washington (DC): Futures Group International, 1999 Sep

47.

Aventin L, Huard P. HIV/AIDS and manufacturing in Abidjan. AIDS Anal Afr 1997; 7 (3): 2–4PubMed

48.

Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709–13PubMedCrossRef

49.

Marseille E, Kahn JG, Saba J. The costs and benefits of employer-sponsored anti-retroviral drug provision [abstract]. 2000 July 11; Durban South Africa. XIII International AIDS Conference 2000, 22

50.

Sendi PP, Bucher HC, Harr T, et al. Cost-effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115–22PubMedCrossRef

51.

International Labor Organization (ILO). A regional study of the impact of HIV/AIDS on the productive labor force, November 1999, Geneva [online]. Available from URL: http://ilo.org/public/english/protection/trav/aids/initiatives.htm [Accessed 2002 Aug 4]

52.

Kwaramba P. The socioeconomic impact of HIV/AIDS on communal agricultural systems in Zimbabwe, Zimbabwe Farmers Union, Harare. UNAIDS 1997 [online]. Available from URL: http://www.un.org/esa/population/publications/ [Accessed 2002 May]

53.

Bollinger L, Stover J, Martin-Correa LJ. The economic impact of AIDS in Benin. US Agency for International Development under contract No. CCP-C-00-95-00023-04. The Futures Group International, 1999 Sep; 1–12

54.

Forsythe S, Roberts M, Wongombe J, et al. Measuring the impacts of HIV/AIDS on Africa’s commercial sector [abstract]. Int Conf. AIDS 1994; 10: 13

55.

Forsythe S, Wienrawee P. The socioeconomic impact of HIV/AIDS in Thailand’s workplace [abstract]; 2000 Jul;. Durban. South Africa. XIII International AIDS Conference 1996; 11: 246

56.

McNeil DG. AIDS stalking Africa’s struggling economies, New York Times, 1998 Nov 15

57.

Over M. The macroeconomic impact of AIDS in sub-Saharan Africa. Technical Working Paper #3. Washington, (DC): World Bank, Africa Technical Department, Population, Health and Nutrition Division, 1992

58.

Rugalema G. HIV/AIDS and the commercial agricultural sector of Kenya: impact, vulnerability, susceptibility and coping strategies. Sustainable Development Department. Food and Organization of the United Nations (FAO) 1999 Jul 3

59.

Rau B, Roberts M, editors. Private sector AIDS policy: businesses managing HIV/AIDS. Arlington (VA): AIDSCAP/Family Health International, 1996

60.

Leigh JP, Lubeck DP, Fanham PG, et al. Hours at work and employment status among HIV-infected patients. AIDS 1995; 9: 81–88PubMedCrossRef

61.

Yelin EH, Greenlatt RM, Hollander H, et al. The impact of HIVrelated illness on employment. Am J Public Health 1991; 81: 79–84PubMedCrossRef

62.

Biggs T, Shah M. The Impact of the AIDS epidemic on African firms. RPED Discussion Paper No. 72, Regional Program on Enterprise Development, The World Bank, 1997 Jan [online]. Available from URL: http://www.un.org/esa/population [Accessed 2002 May]

63.

Rijckborst H. Heineken HIV/AIDS policy: the workplace response to AIDSHeineken HIV/AIDS policy: the workplace response to AIDS. Heineken International Jan 2002 [online]. Available from URL: http://www.smartwork.org/resources/ [Accessed 2002 Oct]

64.

Chibbaro L. DC sued for HIV discrimination: corporation counsel’s office named in disabilities act suit. Washington Blade; 2001 Jul

65.

UNAIDS: putting HIV/AIDS on the business agenda. UNAIDS point of view. Geneva: Nov 1998 [online]. Available from URL: http://worldbank.org/wbi/ [Accessed 2002 Oct]

66.

Schneider P. Economics of HIV/AIDS in developing countries: economic impact of HIV/AIDS on South Africa. Presented at the International AIDS Economic Network (IAEN) symposium. Durban; South Africa, 2000 Jul

67.

[Anonymous]. The worst way to lose talent. The Economist, 2001 Feb [online]. Available from URL: http://www.cid.harvard.edu/ [Accessed 2002 May]

68.

Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13–39PubMedCrossRef

69.

Who is bearing the cost of the AIDS epidemic in Asia? In: Bloom D, Lyons J, editors. Economic implications of AIDS in Asia. New Delhi: United National Development Programme, 1993

70.

Japsen B. Abbott to sell HIV drugs at cost in Africa: other countries may want cuts. Chicago Tribune. Business section. Page 1. 2001 Mar 28

Titel: Economic costs to business of the HIV/AIDS epidemic
verfasst von: Dr Gordon G. Liu
Dr Jeff J. Guo
Scott R. Smith
Publikationsdatum: 01.12.2004
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 18/2004
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422180-00003

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Economic costs to business of the HIV/AIDS epidemic

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 18/2004

The economic implications of non-adherence after renal transplantation

Valuing prevention through economic evaluation

Acknowledgement

The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios

Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma